Breakthroughs Blog

Breakthroughs brings you stories of bright ideas and bold innovations in global health.

The Latest
Philip Kenol
3 takeaways from the inaugural Global Health Security Conference

Last week, the Australian government and the Indo-Pacific Centre for Health Security convened practitioners, researchers, educators, and decision-makers across the fields of public health, medicine, veterinary science, agriculture, government, defense, and anthropology for the first Global Health Security Conference in Sydney to examine the progress made to date in strengthening health systems and to identify gaps and opportunities for enhancing the international community’s ability to respond more efficiently and effectively to future health crises.

Recent

Research Roundup: 3D-printed drugs, R&D in emergency settings, a universal flu vaccine, and more

The US Food and Drug Administration (FDA) approved the first 3D-printed drug last week, paving the way for the technology to be used to customize medical care to individual patients.

GHTC
Read More
When breastfeeding is not possible: How an innovative cup can save lives

Breast milk is the perfect first food for newborns; it provides nutrients and energy that infants need and contains substances that strengthen their immune systems.

Read More
Research Roundup: a Chagas vaccine, new pediatric clinical trial resources, the “Nursery of the Future,” and more

Sabin Vaccine Institute—a member of GHTC—and Texas Children’s Hospital Center for Vaccine Development received a US$1.8 million grant to expedite the research and development of the first therapeutic vaccine for Chagas disease, which is currently undergoing preclinical research by the same team.

GHTC
Read More
New legislation aims to #SaveMomsandKids everywhere

In this guest post, Heather Ignatius—senior policy and advocacy officer at PATH—writes about a new bipartisan piece of legislation to accelerate progress towards ending preventable child and maternal deaths.

PATH
Read More
New report on investment in R&D for HIV prevention highlights 2014 global funding trends

In this guest post, the HIV Vaccines & Microbicides Resource Tracking Working Group—comprised of AVAC as secretariat, the International AIDS Vaccine Initiative, and UNAIDS—discusses its new report examining investment in research and development (R&D) for HIV prevention options.

Read More
Entering the Shark Tank for maternal and newborn health innovation

Last Wednesday 53 teams of innovators gathered at the International Trade Center in Washington, DC, for the Saving Lives at Birth DevelopmentXChange—an event resembling a cross between a science fair and an episode of Shark Tank.

Read More
Research Roundup: a dengue vaccine, a breakthrough HIV treatment, antimicrobial R&D, and more

Later this year, French pharmaceutical company Sanofi plans to launch a vaccine for dengue fever, the first on the market for an infection for which nearly half of the world’s population is at risk.

GHTC
Read More
Research Roundup: an aerosol vaccine for Ebola, software to enable clinical trials, an antibody against dengue fever, and more

An experimental, aerosol vaccine completely prevented infection from Ebola in monkeys, and will be tested in human clinical trials shortly.

GHTC
Read More
PATH/Gabe Bienczycki
How to accelerate innovation to solve the world's most urgent health issues

In this post, Amie Batson, MBA—chief strategy officer at GHTC member PATH—discusses a new PATH-led initiative to identify and showcase lifesaving innovations with the promise to transform global health by 2030 and offers insights into what it will take to accelerate the impact of innovation. This post originally appeared in the Innovation Countdown 2030 Report: Reimagining Global Health.

PATH
Read More
Research Roundup: bacteria-eating viruses, experimental HIV and flu vaccines, and pharmaceutical law

With the looming threat of a post-antibiotic era—in which minor infections are fatal due to growing drug resistance—world leaders are examining remedies for treating bacterial infections from the pre-antibiotic era.

GHTC
Read More
Passing the ball: DNDi transfers malaria therapies to MMV

The Drugs for Neglected Disease initiative (DNDi) and the Medicines for Malaria Venture (MMV)—nonprofit product development partnerships (PDPs) and members of the Global Health Technologies Coalition—have teamed up to ensure two treatments for malaria continue to reach the patients who need them most.

GHTC
Read More
Research Roundup: Drug-resistant TB, regulatory reform in India, a malaria vaccine, and more

A new study published in PLOS Medicine indicates that multi-drug resistant tuberculosis (TB) is less contagious than drug-susceptible TB.

GHTC
Read More
Architect of the Capitol
Celebrating America’s contributions to global health innovation

This Independence Day, GHTC is taking a break from our cookouts and parades to celebrate America’s extraordinary contributions to advancing innovation to save lives around the world.

Read More
PATH/Doune Porter
Four reasons to visit the Contraceptive Technology Innovation Exchange today

Over the past several decades, overall investment in contraceptive R&D has declined dramatically. The result? Renewed commitment and partnerships will be required to ensure that new contraceptive methods advance through the development pipeline and that access to the final products is affordable and equitable.

FHI360
Read More
Research Roundup: a new contraceptive option, China’s role in global health R&D, and vaccines for MERS and pneumonia

Last week, GHTC member PATH launched the Caya® contoured diaphragm in the United States, after developing and testing nearly 200 prototypes to ensure the product was safe, effective, and user friendly.

GHTC
Read More
PATH/Christopher Nelson
Research Roundup: a promising antimalarial and leishmaniasis vaccine, diagnostics for tuberculosis, and more

The Medicines for Malaria Venture (MMV)—a member of the GHTC—and the University of Dundee’s Drug Discovery Unit have developed an antimalarial compound that could treat drug-resistant cases of malaria with a single dose.

GHTC
Read More
PATH/Nguyen Ba Quang
Research Roundup: Middle East Respiratory Syndrome R&D, G7 support for antimicrobial and neglected tropical disease R&D, patient safety and the 21st Century Cures Act, and the contraceptive pipeline

The zoonotic Middle East Respiratory Syndrome (MERS), which World Health Organization (WHO) Director-General Dr. Margaret Chan called “a threat to the entire world” has spread to South Korea. More than 100 cases and 10 deaths have been reported, making it the largest outbreak outside of the Arabian Peninsula.

GHTC
Read More
Research Roundup: cross-sector partnerships to advance drug discovery, global recommendations for contraceptive use, and a diagnostic that detects lifetime viral exposure

The Drugs for Neglected Diseases initiative (DNDi)—a member of the GHTC—is partnering with pharmaceutical companies Eisai Co., Shionogi & Co., Takeda Pharmaceutical, and AstraZeneca to accelerate early-stage research for drugs against Chagas and leishmaniasis.

GHTC
Read More
World Health Assembly roundup: News on global health research and innovation

The 68th World Health Assembly (WHA) in Geneva wrapped up last week after addressing several items that will shape the next few years of global health innovation.

GHTC
Read More
New legislation would strengthen USAID’s role in global health R&D

Update: The Global Health Technologies Coalition is excited to announce that the Global Health Innovation Act (H.R. 2241) passed the House of Representatives on December 18.

GHTC
Read More